Semaglutide Treatment in Type 1 Diabetes
NCT06909006 on ClinicalTrials.gov · last registry update 2025-08-08
A small phase 3 — 122 participants, against a typical 424. Due to report June 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for diabetes and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Nordsjaellands Hospital
- Sponsor type
- Other
- Enrollment
- 122
- Started
- 2025-10
- Primary completion
- 2028-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Body weight
Conditions studied
Obesity in Diabetes · Obesity/Therapy · Type 1 Diabetes Mellitus (T1DM) · Insulin Sensitivity/Resistance · Semaglutide · Lipidomics · Metabolomics · Weight Loss · Glycemic Control for Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.